Page 11 - கிழக்கு கூட்டுறவு புற்றுநோயியல் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed. For the primary endpoint of progression-free survival (PFS) in 99 patients with high-grade serous tumors, those assigned to gemcitabine plus adavosertib had a median PFS of 4.6 months, as compared with 3.0 months with gemcitabine plus placebo (HR 0.55, 95% CI 0.35-0.90, P=0.015), reported Amit Oza, MD, of Princess Margaret Cancer Centre in Toronto, and colleagues. Median overall survival was 11.4 months versus 7.2 months, respectively (HR 0.56, 95% CI 0.35-0.91, P=0.017). In advanced-stage or heavily pretreated high-grade serous ovarian cancer, few options remain after conventional therapy, the authors wrote in

Shibani nicumSarah blagdenIan ingramPrincess margaret cancer centreUniversity of oxfordOxford universityEastern cooperative oncology groupAmit ozaMedpage todayDeputy managing editorMalignant tumor of ovaryMalignant adenomatous neoplasmMass of body structureNeoplastic diseaseசாரா ப்ளாகிட்டேன்ஈயந் இஂக்ரம்